PRAX (Praxis Precision Medicines) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


PRAX Praxis Precision Medicines Inc PRAX
38 GF Score
Price $312.78
GF Value $30.36
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Praxis Precision Medicines Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Praxis Precision Medicines's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

PRAX vs KRYS, CYTK, NUVL: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Praxis Precision Medicines's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Praxis Precision Medicines Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Praxis Precision Medicines's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Praxis Precision Medicines's Margin of Safety % (DCF FCF Based) falls into.


PRAX
38GF Score
Praxis Precision Medicines Inc PRAX
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Praxis Precision Medicines (PRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Praxis Precision Medicines stock appears to be overvalued. The current stock price of $312.78 is trading 930.2% above its estimated GF Value™ of $30.36. GuruFocus considers Praxis Precision Medicines to be Significantly Overvalued.

Key valuation signals for PRAX:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $30.36 vs. price of $312.78 (930.2% above fair value)
  • GF Score™: 38/100 with 1 warning sign

No single metric tells the full story. See the PRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Praxis Precision Medicines Business Description

Address 99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
38GF Score

Get the complete analysis for PRAX

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$312.78
Price
$30.36
GF Value